Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$233.49 USD
-8.76 (-3.62%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $233.88 +0.39 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 1 - 20 ( 189 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Recap: Strong First Quarter of Rezdiffra Launch; Madrigal to Take Europe Too; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q Recap: Rezdiffra Launch Sales Ramp Heavily Weighted to 2H24; Trim PT to $390 on Dilution and Higher OpEx Spend
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rezdiffra Achieves Landmark Approval as the First Therapy Indicated for MASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
All Eyes on Resmetirom March 14 PDUFA; EMA Validates MAA; Significant Model Updates; Raise PT to $405
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for MDGL 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q Recap; MAESTRO-NASH Results Prominently Featured in Presentations at AASLD; Increasing PT to $275; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Resmetirom''s NDA For NASH Fibrosis Under Priority Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
New CEO Takes the Reins, as the FDA''s Acceptance of the Resmetirom NDA, and Setting the PDUFA Date are Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Whole NASH Field Cheers as MAESTRO-NASH Is a Home Run; Raise PT to $225
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MAESTRO-NASH Outcomes NASH Cirrhosis Study Begins; Pivotal MAESTRO-NASH Top-line Results on Target in 4Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Recap; Top-line Readout of Pivotal Phase 3 MAESTRONASH in 4Q Poised to Be a Watershed Event in NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q Recap: Our Positive Thesis Unfazed by Minor Delay in Pivotal Data Readout to 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Results From MAESTRO-NAFLD-1 Tees Up a Low- Risk Pivotal Biopsy NASH Readout in 3Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
We See No Negative Read-Through From the Slight Delay of Top-Line Data From MAESTRO-NAFLD-1 to January 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Post-AASLD KOL Event Highlights Both Strong Non-Invasive Data and Increasing NIT Correlations to Histology Endpoints
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E